DEERFIELD, Ill. / Aug 01, 2024 / Business Wire / Walgreens is now offering flu shots for anyone aged 3 years and up at stores nationwide ahead of respiratory illness season. Individuals and families can visit the pharmacy or schedule an appointment through the Walgreens app, by visiting Walgreens.com/ScheduleVaccine or by calling 1-800-WALGREENS.
Walgreens trusted pharmacy teams are working to keep communities protected this upcoming respiratory season by helping to ensure everyone has convenient and timely options for vaccination, testing and treatment – all in one place.
Data from the CDC and IQVIA show that patients are increasingly turning to pharmacies for their routine vaccinations. According to a 2023 IQVIA study, approximately 70% of adult flu vaccinations were administered in retail pharmacies during flu season.1,2
“Pharmacies continue to be the cornerstone of healthcare in communities across the U.S. and patients rely on our trusted pharmacists for everyday care, and respiratory illness season is no different,” said Rick Gates, chief pharmacy officer, Walgreens. “Our pharmacists play a critical role in ensuring communities stay protected from viruses, providing accessible, quick and routine preventive services, including vaccinations, testing and treatment.”
More than 50,000 immunizing Walgreens pharmacy team members continue to play a critical role in helping to protect patients and their families from vaccine-preventable illnesses. Since 2010, they have administered more than 105 million vaccinations in communities throughout the U.S. Thanks to their efforts, neighborhood pharmacies like Walgreens continue to be the most accessible destinations for care during fall respiratory virus season.
How to prepare for a visit:
About Walgreens
Walgreens (www.walgreens.com) is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of “more joyful lives through better health,” Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company’s pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation’s most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement.
1 IQVIA. Trends in vaccine administration in the United States. January 13, 2023. www.iqvia.com/insights/the-iqvia-institute/reports/trends-in-vaccine-administration-in-the-united-states
2 Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults, United States. May 4, 2024. https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-administered.html.
*Please note that walk-in appointments are based on availability.
Last Trade: | US$8.21 |
Daily Change: | -0.08 -0.97 |
Daily Volume: | 24,873,335 |
Market Cap: | US$7.090B |
October 15, 2024 October 07, 2024 August 19, 2024 August 01, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB